Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma

Hiroo Imai; Keigo Komine; Shin Takahashi; Ken Saijo; Yoshinari Okada; Akihiro Kobayashi; Akira Okita; Sonoko Chikamatsu; Yuki Kasahara; Masahiro Takahashi; Takayuki Oishi; Hidekazu Shirota; Masanobu Takahashi; Hideki Shimodaira; Chikashi Ishioka

doi:10.1159/000444122

Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma

Hiroo Imai, Keigo Komine, Shin Takahashi, Ken Saijo, Yoshinari Okada, Akihiro Kobayashi, Akira Okita, Sonoko Chikamatsu, Yuki Kasahara, Masahiro Takahashi, Takayuki Oishi, Hidekazu Shirota, Masanobu Takahashi, Hideki Shimodaira, Chikashi Ishioka

Tohoku University

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Background: Incomplete cross-resistances between paclitaxel (PTX) and docetaxel (DTX) has been demonstrated in several types of cancer. The objective of the present study was to assess the existence of cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Methods: Patients in the PTX group received PTX without DTX pretreatment, patients in the prior DTX (Pr-DTX) group received PTX after the development of resistance to DTX, and patients in the DTX group received DTX without subsequent PTX treatment. Results: A total of 73 patients were enrolled. The response rates to PTX in the PTX and Pr-DTX groups were 22.7 and 20.0%, respectively. The median progression-free survival times from the first day of PTX treatment in the PTX and Pr-DTX groups were 113 (95% CI 56-154) and 97 days (95% CI 36-189), respectively. The median overall survival times from the first day of DTX treatment in the Pr-DTX and DTX groups were 315 (95% CI 124-453) and 148 days (95% CI 139-177), respectively. Conclusions: There is no or incomplete clinical cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Replacement of DTX with PTX is a suitable treatment option for patients with DTX-resistant esophageal squamous cell carcinoma.

Original language	English
Pages (from-to)	262-268
Number of pages	7
Journal	Chemotherapy
Volume	61
Issue number	5
DOIs	https://doi.org/10.1159/000444122
Publication status	Published - 2016 Feb 25

Keywords

Cross-resistance
Docetaxel
Esophageal cancer
Paclitaxel

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000444122

Cite this

Imai, H., Komine, K., Takahashi, S., Saijo, K., Okada, Y., Kobayashi, A., Okita, A., Chikamatsu, S., Kasahara, Y., Takahashi, M., Oishi, T., Shirota, H., Takahashi, M., Shimodaira, H., & Ishioka, C. (2016). Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma. Chemotherapy, 61(5), 262-268. https://doi.org/10.1159/000444122

@article{d12c18cb991940378e0f295deeca9fb1,

title = "Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma",

abstract = "Background: Incomplete cross-resistances between paclitaxel (PTX) and docetaxel (DTX) has been demonstrated in several types of cancer. The objective of the present study was to assess the existence of cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Methods: Patients in the PTX group received PTX without DTX pretreatment, patients in the prior DTX (Pr-DTX) group received PTX after the development of resistance to DTX, and patients in the DTX group received DTX without subsequent PTX treatment. Results: A total of 73 patients were enrolled. The response rates to PTX in the PTX and Pr-DTX groups were 22.7 and 20.0%, respectively. The median progression-free survival times from the first day of PTX treatment in the PTX and Pr-DTX groups were 113 (95% CI 56-154) and 97 days (95% CI 36-189), respectively. The median overall survival times from the first day of DTX treatment in the Pr-DTX and DTX groups were 315 (95% CI 124-453) and 148 days (95% CI 139-177), respectively. Conclusions: There is no or incomplete clinical cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Replacement of DTX with PTX is a suitable treatment option for patients with DTX-resistant esophageal squamous cell carcinoma.",

keywords = "Cross-resistance, Docetaxel, Esophageal cancer, Paclitaxel",

author = "Hiroo Imai and Keigo Komine and Shin Takahashi and Ken Saijo and Yoshinari Okada and Akihiro Kobayashi and Akira Okita and Sonoko Chikamatsu and Yuki Kasahara and Masahiro Takahashi and Takayuki Oishi and Hidekazu Shirota and Masanobu Takahashi and Hideki Shimodaira and Chikashi Ishioka",

note = "Publisher Copyright: {\textcopyright} 2016 S. Karger AG, Basel.",

year = "2016",

month = feb,

day = "25",

doi = "10.1159/000444122",

language = "English",

volume = "61",

pages = "262--268",

journal = "Chemotherapy",

issn = "0009-3157",

publisher = "S. Karger AG",

number = "5",

}

Imai, H , Komine, K, Takahashi, S, Saijo, K, Okada, Y, Kobayashi, A, Okita, A, Chikamatsu, S, Kasahara, Y, Takahashi, M, Oishi, T, Shirota, H , Takahashi, M, Shimodaira, H & Ishioka, C 2016, 'Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma', Chemotherapy, vol. 61, no. 5, pp. 262-268. https://doi.org/10.1159/000444122

TY - JOUR

T1 - Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma

AU - Imai, Hiroo

AU - Komine, Keigo

AU - Takahashi, Shin

AU - Saijo, Ken

AU - Okada, Yoshinari

AU - Kobayashi, Akihiro

AU - Okita, Akira

AU - Chikamatsu, Sonoko

AU - Kasahara, Yuki

AU - Takahashi, Masahiro

AU - Oishi, Takayuki

AU - Shirota, Hidekazu

AU - Takahashi, Masanobu

AU - Shimodaira, Hideki

AU - Ishioka, Chikashi

PY - 2016/2/25

Y1 - 2016/2/25

N2 - Background: Incomplete cross-resistances between paclitaxel (PTX) and docetaxel (DTX) has been demonstrated in several types of cancer. The objective of the present study was to assess the existence of cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Methods: Patients in the PTX group received PTX without DTX pretreatment, patients in the prior DTX (Pr-DTX) group received PTX after the development of resistance to DTX, and patients in the DTX group received DTX without subsequent PTX treatment. Results: A total of 73 patients were enrolled. The response rates to PTX in the PTX and Pr-DTX groups were 22.7 and 20.0%, respectively. The median progression-free survival times from the first day of PTX treatment in the PTX and Pr-DTX groups were 113 (95% CI 56-154) and 97 days (95% CI 36-189), respectively. The median overall survival times from the first day of DTX treatment in the Pr-DTX and DTX groups were 315 (95% CI 124-453) and 148 days (95% CI 139-177), respectively. Conclusions: There is no or incomplete clinical cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Replacement of DTX with PTX is a suitable treatment option for patients with DTX-resistant esophageal squamous cell carcinoma.

AB - Background: Incomplete cross-resistances between paclitaxel (PTX) and docetaxel (DTX) has been demonstrated in several types of cancer. The objective of the present study was to assess the existence of cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Methods: Patients in the PTX group received PTX without DTX pretreatment, patients in the prior DTX (Pr-DTX) group received PTX after the development of resistance to DTX, and patients in the DTX group received DTX without subsequent PTX treatment. Results: A total of 73 patients were enrolled. The response rates to PTX in the PTX and Pr-DTX groups were 22.7 and 20.0%, respectively. The median progression-free survival times from the first day of PTX treatment in the PTX and Pr-DTX groups were 113 (95% CI 56-154) and 97 days (95% CI 36-189), respectively. The median overall survival times from the first day of DTX treatment in the Pr-DTX and DTX groups were 315 (95% CI 124-453) and 148 days (95% CI 139-177), respectively. Conclusions: There is no or incomplete clinical cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Replacement of DTX with PTX is a suitable treatment option for patients with DTX-resistant esophageal squamous cell carcinoma.

KW - Cross-resistance

KW - Docetaxel

KW - Esophageal cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=84964043421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964043421&partnerID=8YFLogxK

U2 - 10.1159/000444122

DO - 10.1159/000444122

M3 - Article

C2 - 27043795

AN - SCOPUS:84964043421

SN - 0009-3157

VL - 61

SP - 262

EP - 268

JO - Chemotherapy

JF - Chemotherapy

IS - 5

ER -

Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this